November 23, 2016 - By Peter Kolinski
In a research report revealed on today, Maxim Group restate their Buy rating on Juno Therapeutics (NASDAQ:JUNO)‘s stock. The PT suggests a potential upside of 13.79% from firm’s last stock close price.
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. $73 is the highest target while $39 is the lowest. The $51.80 average target is 136.31% above today’s ($21.92) stock price. Juno Therapeutics Inc has been the topic of 18 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by Northland Capital given on Wednesday, July 22. Goldman Sachs initiated Juno Therapeutics Inc (NASDAQ:JUNO) rating on Wednesday, November 18. Goldman Sachs has “Neutral” rating and $50 price target. The stock has “Hold” rating given by Standpoint Research on Thursday, October 29. As per Wednesday, July 6, the company rating was initiated by Barclays Capital. On Friday, July 8 the stock rating was downgraded by JP Morgan to “Neutral”. The firm has “Buy” rating given on Friday, January 29 by Suntrust Robinson. Standpoint Research initiated Juno Therapeutics Inc (NASDAQ:JUNO) rating on Monday, August 24. Standpoint Research has “Buy” rating and $47.0 price target. The firm has “Buy” rating by Standpoint Research given on Tuesday, December 15. Maxim Group maintained the stock with “Buy” rating in Friday, August 5 report. The firm has “Outperform” rating given on Friday, July 8 by FBR Capital.
About 14.46M shares traded hands or 897.24% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 32.60% since April 21, 2016 and is downtrending. It has underperformed by 37.93% the S&P500.
Insitutional Activity: The institutional sentiment increased to 1.4 in Q2 2016. Its up 0.06, from 1.34 in 2016Q1. The ratio improved, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Bamco New York has 0.02% invested in the company for 100,525 shares. Aqr Cap Mngmt Limited Liability Corp accumulated 232,432 shares or 0.02% of the stock. Cubist Systematic Strategies Ltd Limited Liability Company reported 12,938 shares or 0.03% of all its holdings. Pittenger & Anderson accumulated 0% or 45 shares. California Public Employees Retirement Sys last reported 0% of its portfolio in the stock. Brick Kyle owns 500 shares or 0.02% of their US portfolio. Rockefeller Finance Service Incorporated reported 226 shares or 0% of all its holdings. State Of Wisconsin Board has invested 0.01% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Teachers holds 52,548 shares or 0% of its portfolio. Seven Eight Cap Ltd Liability Corp reported 1,001 shares or 0.01% of all its holdings. Verition Fund Mngmt Ltd Company has invested 0.03% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Tocqueville Asset Mngmt L P holds 34,200 shares or 0.02% of its portfolio. Tradewinds Capital Mngmt Ltd Liability Co last reported 0.04% of its portfolio in the stock. Vident Inv Advisory Limited Liability Co has 0.09% invested in the company for 15,776 shares. Point72 Asia (Hong Kong) Ltd accumulated 100 shares or 0% of the stock.
Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $2.21 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
More recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fortune.com which released: “Juno Therapeutics’ Shares Sink After 2 More Deaths in Leukemia Drug Trial” on November 23, 2016. Also Marketwatch.com published the news titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …” on November 23, 2016. Fool.com‘s news article titled: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” with publication date: November 03, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.